7 articles
2026-06-297 min readGLP-1 & weight loss
TRIUMPH-1 is an important research update, but a sponsor's topline announcement is not FDA approval, a complete peer-reviewed record, or patient guidance.
2026-06-277 min readGLP-1 & weight loss
A research-literacy guide to retatrutide's phase 2 study design, endpoints, limitations, and why published findings are not approval or patient guidance.
2026-05-168 min readGLP-1 & weight loss
FDA shortage status changed the GLP-1 compounding landscape. Here is how patients can ask safer questions about prescriptions, pharmacy sourcing, dosing, and alternatives without assuming every compounded option is available.
2026-05-169 min readGLP-1 & weight loss
GLP-1 microdosing is trending, but low dose does not mean low risk. Learn what evidence exists, what is still uncertain, and which safety questions to ask before changing a prescription plan.
2026-05-166 min readGLP-1 & weight loss
Retatrutide remains a research-stage drug without an FDA-approved finished-drug label. This guide explains what clinical trials, regulatory review, and online availability claims do—and do not—mean.
2026-05-169 min readGLP-1 & weight loss
Stopping a GLP-1 medication can lead to appetite return, weight regain, and loss of some cardiometabolic improvements for many people. Learn what to discuss with a clinician before tapering, pausing, or stopping semaglutide, tirzepatide, Wegovy, Ozempic, Zepbound, or Mounjaro.
2026-04-016 min readGLP-1 & weight loss
Compounded semaglutide and tirzepatide are patient-specific, non-FDA-approved finished drug products. Here is how that pharmacy pathway differs from FDA-approved branded products.